Both dabrafenib and vemurafenib monotherapy as well as dabrafenib/trametinib and vemurafenib/cobimetinib combination therapies are approved indications for unresectable stage III or metastatic melanoma that is BRAF V600E–mutated. Here, BRAF is linked to metastatic melanoma.